Want to see MBX full AI Analyst Report?
MBX Stock Chart & Stats
$33.77
-$0.30(-2.05%)
At close: 4:00 PM EST
$33.77
-$0.30(-2.05%)
Day’s Range― - ―
52-Week Range$9.63 - $66.55
Previous CloseN/A
Volume52.29K
Average Volume (3M)947.88K
Market Cap
$2.94B
Enterprise Value$1.35B
Total Cash (Recent Filing)$439.98M
Total Debt (Recent Filing)$555.00K
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Aug 06, 2026EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.20
Shares Outstanding47,597,534
10 Day Avg. Volume1,108,351
30 Day Avg. Volume947,879
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)3.12
Price to Sales (P/S)0.00
P/FCF Ratio-14.06
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.04K
Enterprise Value/Ebitda-15.66
Forecast
1Y Price Target
$74.75Price Target Upside121.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.81
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and a rebuilt equity base materially reduce near‑term solvency risk and increase optionality to fund pivotal trials. This strengthens the firm’s ability to execute clinical milestones without immediate default risk, supporting durable operational continuity.
De‑risked Lead Asset (canvuparatide)Robust Phase 2 and one‑year data for canvuparatide meaningfully de‑risk the lead program, justifying advancement to a Phase 3 pivotal trial. Successful progression to registrational studies creates a clear pathway to commercial opportunity and long‑term value creation for a disease‑modifying therapy.
Pipeline Breadth & Peptide PlatformPositive early obesity signals and multiple nominated candidates show the company’s peptide engineering platform can generate differentiated, long‑duration programs. A diversified endocrine/metabolic pipeline increases potential win paths and the likelihood of sustained value creation from multiple indications.
Bears Say
Accelerating Cash BurnOperating cash flow has deteriorated materially, signaling accelerating cash consumption to fund trials and operations. This persistent negative cash flow creates ongoing financing needs, increases dilution risk, and constrains strategic flexibility over a multi‑quarter horizon despite low debt.
Pre‑revenue With Widening LossesThe company remains pre‑revenue while losses have expanded materially, reflecting rising R&D and operating intensity. Without product sales, sustained losses rely on external capital; extended negative profitability erodes shareholder value and heightens dependence on successful clinical outcomes.
Concentration Of R&D ResourcesDeliberate reallocation away from imapextide narrows program diversification and concentrates risk on fewer lead programs. While sharpening focus can accelerate priority assets, it raises downside if prioritized trials fail and limits alternative near‑term pathways to mitigate binary outcomes.
MBX Biosciences, Inc. News
MBX FAQ
What was MBX Biosciences, Inc.’s price range in the past 12 months?
MBX Biosciences, Inc. lowest stock price was $9.63 and its highest was $66.55 in the past 12 months.
What is MBX Biosciences, Inc.’s market cap?
MBX Biosciences, Inc.’s market cap is $2.94B.
When is MBX Biosciences, Inc.’s upcoming earnings report date?
MBX Biosciences, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were MBX Biosciences, Inc.’s earnings last quarter?
MBX Biosciences, Inc. released its earnings results on May 07, 2026. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.585 by $0.075.
Is MBX Biosciences, Inc. overvalued?
According to Wall Street analysts MBX Biosciences, Inc.’s price is currently Undervalued.
Does MBX Biosciences, Inc. pay dividends?
MBX Biosciences, Inc. does not currently pay dividends.
What is MBX Biosciences, Inc.’s EPS estimate?
MBX Biosciences, Inc.’s EPS estimate is -0.64.
How many shares outstanding does MBX Biosciences, Inc. have?
MBX Biosciences, Inc. has 47,597,534 shares outstanding.
What happened to MBX Biosciences, Inc.’s price movement after its last earnings report?
MBX Biosciences, Inc. reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.585. Following the earnings report the stock price went up 8.064%.
Which hedge fund is a major shareholder of MBX Biosciences, Inc.?
Currently, no hedge funds are holding shares in MBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MBX Biosciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.75 (121.35% Upside)
$74.75 (121.35% Upside)
Blogger Sentiment
Bullish
MBX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 501.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $24.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.5%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
394.80%
12-Months-Change
Fundamentals
Return on Equity
-24.50%
Trailing 12-Months
Asset Growth
84.08%
Trailing 12-Months
Company Description
MBX Biosciences, Inc.
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
MBX Stock 12 Month Forecast
Average Price Target
$74.75
▲(121.35% Upside)
Technical Analysis
Ownership Overview
25.99% Insiders
10.26% Mutual Funds
4.83% Other Institutional Investors
50.54% Public Companies and
Individual Investors